The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,425.00
Bid: 2,370.00
Ask: 2,385.00
Change: 50.00 (2.11%)
Spread: 15.00 (0.633%)
Open: 2,340.00
High: 2,425.00
Low: 2,340.00
Prev. Close: 2,375.00
OXIG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

8 Sep 2015 07:00

RNS Number : 3461Y
Oxford Instruments PLC
08 September 2015
 



Embargoed until 7:00 am on 8th September 2015

 

Oxford Instruments plc

Chairman's AGM Statement 2015

 

 

Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, is holding its annual general meeting today in which the Chairman, Nigel Keen will make the following statement:

 

"As previously reported, the year to March 2015 was a testing time for Oxford Instruments. In the first half of the year, despite overall increases in orders and revenues, progress was adversely impacted by weaker demand in Japan and tough trading conditions for our Plasma Technology business. In the second half we encountered a combination of headwinds that unexpectedly put our short-term performance projections off-course. Three factors were primarily at play: the sudden tightening of trade sanctions for sales to Russia, a slower-than-expected recovery in Japanese markets, and weaker trading in our Industrial Analysis business.

 

In response to the downturn in trading conditions, we rapidly implemented a wide-ranging programme to bring our cost-base in line with our trading environment. Our team has rallied to the challenge and I want to thank all our staff for responding so vigorously and for retaining their enthusiasm and creativity despite the difficult conditions.

 

In addition to our focus on restructuring the Group, we have taken positive strategic steps that will help drive future growth. Last year we increased our investment in R&D to underpin future organic growth. This year, we acquired Medical Imaging Resources in the USA, and formed a joint venture between our Omicron business and Scienta Scientific AB in Sweden. I am pleased to say that both ventures are performing as planned.

 

Professor Sir Richard Friend joined the Board of Oxford Instruments on 1 September 2014. Richard brings with him strong technical capability and valuable contacts in the worldwide academic community and we welcome him as a director.

 

Current Trading

 

Adjusted operating profit is ahead of the same period last year benefiting from the reduction in overheads that resulted from last year's restructuring. Percentage gross margins have been maintained.

 

The slow start to the year that we discussed in our June results statement has meant that orders and sales for the year to date are below the same period last year on a constant currency organic basis. However as expected, orders in June and July have been significantly ahead of the first two months of the year.

 

NanoTechnology Tools

 

Excluding the Omicron business which was put into a Joint Venture earlier in the year, revenues are ahead of the same period in the previous year and margins have improved due to a positive product mix and the effects of the cost reduction programme announced last year.

Performance in Asia has been strong in our NanoCharacterisation sector but more subdued in the more R&D focused NanoSolutions sector.

 

In North America and Europe the markets are relatively flat.

 

Industrial Products

 

We are seeing a modest decline in orders in Industrial Products. This is most marked in our Industrial Analysis business in China where demand for products for recycling and in the metals analysis markets is softer.

 

Competition from new Asian entrants in the MRI market has resulted in the established MRI systems manufacturers exerting significant price pressure on their supply base. Consequently we believe that sales of superconducting wire to these manufacturers will be down some 15% on the prior year at reduced margins. We believe that this will impact this year's profit in this business by approximately £2.5m. Negotiations with these customers are currently ongoing, the outcome of which is likely to adversely affect future years.

 

Service

 

The Service sector is performing well and is ahead of prior year on a like for like and reported basis.

 

 

Outlook

 

Whilst the macro economic backdrop remains challenging, our Nanotechnologies and Service businesses remain robust and are benefiting from the restructuring actions of last year. However we have reduced our expectations for the full year primarily due to the changing market dynamics in our superconducting wire business described above and the difficult trading environment for our Chinese Industrial Products division.

 

Nanotechnology will continue to yield long term structural growth in demand for high technology tools. Our strategy is focused on growing the business in our core markets of physical and materials science, and exploiting convergence to expand into life sciences. This, combined with our continuing investment in new products, underpins the Board's view that the Group is well positioned to deliver its growth strategy over the medium term."

 

Jonathan Flint (Chief Executive) and Kevin Boyd (Group Finance Director) will host a conference call for analysts and investors on this announcement at 09:00 am (UK time), today 8 September. To join the call, please use the dial-in numbers below:Dial: +44 02031394830PIN: 94742637#

 

Enquiries:

 

Oxford Instruments plc

Tel: 01865 393200

Jonathan Flint, Chief Executive

Kevin Boyd, Group Finance Director

 

MHP Communications

Tel: 020 3128 8100

Rachel Hirst / Jamie Ricketts

 

Notes to Editors  

 

About Oxford Instruments plc

Oxford Instruments designs, supplies and supports high-technology tools and systems with a focus on research and industrial applications. Innovation has been the driving force behind Oxford Instruments' growth and success for over 50 years, and its strategy is to effect the successful commercialisation of these ideas by bringing them to market in a timely and customer-focused fashion.

The first technology business to be spun out from Oxford University, Oxford Instruments is now a global company with over 2000 staff worldwide and is listed on the London Stock Exchange (OXIG). Its objective is to be the leading provider of new generation tools and systems for the research and industrial sectors with a focus on nanotechnology. Its key market sectors include nano-fabrication and nano-materials. The company's strategy is to expand the business into the life sciences arena, where nanotechnology and biotechnology intersect

This involves the combination of core technologies in areas such as low temperature, high magnetic field and ultra high vacuum environments; Nuclear Magnetic Resonance; x-ray, electron, laser and optical based metrology; atomic force microscopy; optical imaging; advanced growth, deposition and etching.

Oxford Instruments aims to pursue responsible development and deeper understanding of our world through science and technology. Its products, expertise, and ideas address global issues such as energy, environment, security and health.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMUBURRVOAKRUR
Date   Source Headline
2nd Mar 202012:06 pmPRNTotal Voting Rights
2nd Mar 202012:02 pmRNSPrice Monitoring Extension
27th Feb 202012:07 pmRNSSecond Price Monitoring Extn
27th Feb 202012:02 pmRNSPrice Monitoring Extension
24th Feb 20207:00 amRNSDisposal of OI Healthcare business in the US
10th Feb 20201:49 pmPRNDirector/PDMR Shareholding
3rd Feb 202012:41 pmPRNTotal Voting Rights
29th Jan 20207:00 amRNSSale of Minority Share in Scienta Omicron
23rd Jan 202010:52 amPRNAdditional Listing
13th Jan 20209:55 amPRNDirector/PDMR Shareholding
10th Jan 202012:02 pmRNSPrice Monitoring Extension
9th Jan 202010:42 amPRNTotal Voting Rights
9th Jan 20209:41 amPRNBlocklisting - Interim Review
3rd Jan 20208:36 amPRNHolding(s) in Company
11th Dec 20194:03 pmPRNDirector/PDMR Shareholding
2nd Dec 20192:54 pmPRNTotal Voting Rights
12th Nov 201912:49 pmPRNDirector/PDMR Shareholding
12th Nov 20197:00 amRNSHalf-year Report
11th Oct 201912:02 pmRNSPrice Monitoring Extension
10th Oct 20194:34 pmPRNDirector/PDMR Shareholding
3rd Oct 201911:00 amPRNTotal Voting Rights
11th Sep 20193:30 pmPRNDirector/PDMR Shareholding
11th Sep 201912:12 pmPRNResult of AGM
11th Sep 201910:50 amPRNDirector/PDMR Shareholding
10th Sep 20197:00 amRNSChairman's AGM Statement 2019
29th Aug 201912:07 pmRNSSecond Price Monitoring Extn
29th Aug 201912:02 pmRNSPrice Monitoring Extension
22nd Aug 20191:24 pmPRNHolding(s) in Company
13th Aug 201910:26 amPRNDirector/PDMR Shareholding
15th Jul 20194:26 pmPRNDirector/PDMR Shareholding
11th Jul 201911:49 amPRNDirector/PDMR Shareholding
1st Jul 201911:07 amPRNBlocklisting - Interim Review
27th Jun 20195:01 pmPRNHolding(s) in Company
26th Jun 20195:30 pmRNSRPC Group
11th Jun 20191:02 pmPRNDirector/PDMR Shareholding
11th Jun 20197:00 amRNSFinal Results
30th May 20191:18 pmPRNHolding(s) in Company
13th May 201910:27 amPRNDirector/PDMR Shareholding
11th Apr 201912:00 pmPRNDirector/PDMR Shareholding
11th Apr 20197:00 amRNSTrading Statement
22nd Mar 20197:00 amRNSContract win
11th Mar 20191:40 pmPRNDirector/PDMR Shareholding
12th Feb 20191:32 pmPRNDirector/PDMR Shareholding
1st Feb 20199:56 amPRNDirector Declaration
15th Jan 201910:28 amPRNAdditional Listing
14th Jan 20194:01 pmPRNBlocklisting - Interim Review
11th Jan 201910:28 amPRNDirector/PDMR Shareholding
3rd Jan 201912:26 pmPRNDirector Declaration
2nd Jan 201911:33 amPRNHolding(s) in Company
17th Dec 20181:22 pmPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.